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NATRIURETIC PEPTIDES AS A HUMORAL LINK BETWEEN THE 
 
HEART AND THE GASTROINTETSINAL SYSTEM 
 
 
Anteneh Addisu 
 
 
         ABSTRACT 
 
Natriuretic peptides are a family of hormones released by several 
different tissues and exert various physiological functions by coupling 
with cell surface receptors and increasing intracellular cyclic gyanylyl 
monophosphate (cGMP). Atrial Natriuretic Peptide (ANP) and B-type 
Natriuretic Peptide (BNP) are released in response to mechanical 
stretch of the atrial or ventricular myocardium, respectively and their 
plasma level is markedly elevated during myocardial infarction and 
heart failure. Heart failure in turn is associated with symptoms 
suggestive of perturbed gastrointestinal function such as nausea, 
indigestion and malabsorption. 
Intragastric pressure was monitored using a balloon catheter in 
anesthetized mice. The pressure before and after treatment with a 10 
ng/g intravenous dose of ANP, BNP, CNP or vehicle was compared and 
analyzed. All the natriuretic peptides significantly decreased 
intragastric pressure compared to vehicle. These effects were 
 ix
attenuated or absent in natriuretic peptide receptor type-A (NPR-A) 
knockout mice. Furthermore, the effect of BNP on gastric emptying 
and intestinal absorption was examined using a meal consisting of 
fluorescence labeled dextran gavage fed to awake mice. BNP 
significantly decreased gastric emptying and absorption as compared 
to vehicle control. Using a cryoinfarction acute myocardial injury 
model, our investigation showed that mice with acute cryoinfarction 
had a significantly lower gastric emptying and absorption of a gavage 
fed meal compared to sham. Circulating BNP levels were significantly 
higher in the infarcted mice compared to controls. Immunostaining 
showed amplified distribution of the non-muscle myosin type-II (MCH-
II) in BNP treated mice. MCH-II is involved in movement of intestinal 
villi. 
In summary, natriuretic peptides in general and BNP in 
particular, have gastrointestinal effects including reduced gastric 
contractility, emptying and absorption. In addition to their effect on 
smooth muscle relaxation mediated by cGMP, natriuretic peptides 
appear to have an effect on distribution of MHC-II in cells of the 
intestinal villi.   
We postulate that these effects are aimed at mediating a 
‘communication’ between the cardiovascular and gastrointestinal 
systems. Further characterization of such a link will not only add a 
 x
dimension to the understanding of the pathophysiology of heart failure 
but also enhances the search for further therapeutic targets. 
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CHAPTER ONE 
 
INTRODUCTION AND BACKGROUND 
 
 
Since maintaining body fluid volume is one of the most tightly 
regulated physiological functions, animals have evolved with 
increasingly sophisticated mechanisms for rapidly detecting and 
responding to changes in fluid volume. In vertebrates, the vascular low 
pressure volume sensors are embedded within the walls of the 
myocardium and large pulmonary blood vessels. These volume sensors 
detect changes in pressure (or volume) induced stretch of the vessel 
and myocardial wall. Signals from these receptors travel via afferent 
fibers of the vagus nerve to the solitary tract nucleus of the medulla 
oblongata in the brain stem (Donald & Shepherd, 1979; Thorén et al., 
1976). Feedback activation or deactivation of neural signals back to 
the target organs then modulate mechanisms that result in more or 
less diuresis, natriuresis or vascular tone depending on the body’s 
requirement. However even as early as the first half of the last century 
there were studies that suggested there may be humoral (non 
neuronal) system of receptors that responded to the change in 
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pressure or volume stretching the atrial myocardium. For instance, 
expansion of plasma volume by blood transfusion to healthy dogs was  
shown to increase urine flow (Metcalf, 1944). Similarly infusion of 
isooncotic solution of albumin was shown to produce marked diuresis 
in human volunteers (Welt & Orloff, 1951). Strauss et al reported that 
infusion of isotonic (0.9%) saline to healthy volunteers increased 
“water diuresis’’ during recumbency; and they noted that the body 
position influenced how the infused volume is distributed and sensed 
by the atrium (Strauss et al., 1951). The role of atrial stretch in such 
volume induced diuresis was already experimentally established in the 
mid 1950s (Henry & Pearce, 1956). Henry and colleagues used a 
balloon to distend the atrium in dogs and showed that urine output 
was increased corresponding to the degree of atrial distension. In their 
paper entitled “The possible role of cardiac atrial stretch receptors in 
the induction of changes in urine flow”, Henry and Pearce noted that 
vagotomy did not abolish the diuretic response to isotonic infusions; 
and this led to their conclusion in 1956 that “the body may be 
provided with other receptors or pathways by which it receives 
information which makes possible the regulation of blood volume by 
the control of urine flow”.  
Nevertheless, until only a little over two decades ago; the 
outcome of the activation of atrial and venous stretch receptors was 
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believed to almost entirely depend on the modulation of autonomic 
nerve activity or varying levels of secretion of antidiuretic hormone 
(ADH) from the neurohypohysis. 
In 1980 Adolfo de Bold reported his seminal discovery that 
intravenous injection of extract from the rat atrium produced a marked 
diuresis (de Bold et al., 1981). 
Thus it became apparent that the atrium produced a diuretic and 
natriuretic substance that was released into the circulation and worked 
through a receptor system that is distinct from the neurally mediated 
feedback inhibition. This natriuretic ‘substance’ was initially termed 
atrial natriuretic factor (ANF). With this discovery, it also became 
apparent that the heart has an endocrine function and directly 
‘communicates’ with the kidney by virtue of its own cardiac hormone 
systems.   
The presence of granular structures in the atrial myocytes of 
several different species was one of the earliest findings of the advent 
of electron microscopy (Jamieson & Palade, 1964; Kisch, 1956; Palade, 
1961). Moreover, the possible relationship between atrial granules and 
the degree of sensitivity of the atrium to volume or salt loading was 
suggested as early as 1976 (Marie et al., 1976). However it was with 
de Bold’s seminal experiments that the content of these atrial granules 
was clearly hinted to be a potent natriuretic substance that directly 
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influenced renal handling of salt and water (de Bold et al., 1981; de 
Bold., 1985). The atrial natriuretic factor was later determined to be a 
peptide produced by the atrial myocardium (Currie et al., 1984; Flynn 
TG, 1983; Misono et al., 1984) and it is currently more commonly 
referred to as Atrial Natriuretic Peptide (ANP). The ANP gene was 
subsequently sequenced revealing the remarkable similarity and 
genetic conservation of the natriuretic peptides across many species 
(Seidman et al., 1984). 
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The Natriuretic Peptides 
The identification of ANP in 1985 was soon followed by the 
discovery of a similar peptide in porcine brain (Sudoh et al., 1988)  
hence  termed as brain natriuretic peptide (BNP). However it was later 
discovered that BNP was another cardiac hormone and is actually 
absent in brains of some species (Ogawa et al., 1991; Ogawa et al., 
1990). In 1990, C-type natriuretic peptide (CNP) was isolated from the 
brain of pigs, bullfrogs and two species of teleost fishes (Sudoh et al., 
1990; Suzuki et al., 1991; Yoshihara et al., 1990). The three 
natriuretic peptides share a common structural feature, a conserved 
17 amino acid ring with variable N- and C-terminal sequences (figure 
1). The number of amino acid residues extending from the C terminal 
is usually 5 for ANP, 6 for BNP and 0 for CNP with few exceptions. 
Thus the C-terminal sequence appears to be a major determinant of 
biological activity of the natriuretic peptides. CNP is the most 
conserved of the three peptides across species and it is believed to 
have evolved earlier in the phylogenetic tree, ANP and BNP being 
derived from it at a later point in evolution. In recent years a fourth 
natriuretic peptide, a 38 amino acid peptide known as deandropsis 
natriuretic peptide (DNP) has been isolated from the venom of the 
green mamba snake (Munagala et al., 2004). Immunoreactivity to DNP 
has been shown in human and rodent plasma (Johns et al., 2007; 
Schirger et al., 1999). However, a gene coding for it has not yet been 
isolated and the physiological significance of DNP in humans (if any) 
remains poorly understood.  
 
Figure 1. Linear peptide structure of the natriuretic peptides 
 
 
 
                 Adapted from (Cea, 2005)  
In humans, the ANP and BNP genes are localized in tandem on 
chromosome 1. Transcription of the ANP gene yields an mRNA that 
encodes a 151 amino acid metabolic precursor known as preproANP. 
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PreproANP is rapidly converted to a 126 amino acid peptide proANP. 
ProANP is the predominant storage form of ANP and the major 
constituent of atrial granules. Atrial distension is the major signal for 
the release of ANP (Anderson et al., 1986; Dietz, 1984; Dietz et al., 
1991; Kinnunen et al., 1992; Sato et al., 1986). When such a signal is 
sensed; proANP is cleaved by a cardiac serine protease (corin) into an 
amino fragment pro-ANP (amino acids 1-98) and ANP, the biologically 
active fragment (amino acids 99-126) (Bloch et al., 1986; Vuolteenaho 
et al., 1985). Further cleavage of proANP (1-98) results in more 
peptide fragments (1-30) and (31-67); these fragments also have 
biological activity and neutralization of proANP 1-30 was shown to 
exacerbate hypertension in spontaneously hypertensive rats (Dietz et 
al., 2001; Dietz et al., 2003; Dietz et al., 1995; Dietz & Villarreal, 
1995; Vesely et al., 1999). The amino acid sequences of the main 
biologically active hormone ANP 99-126 are identical in all mammalian 
species except at residue 110, which is methionine in humans 
(Kangawa et al., 1984; Lewicki et al., 1986; Vlasuk et al., 1986) but 
isoleucine in rats, mice and rabbits (Oikawa et al., 1985; Seidman et 
al., 1984; Yamanaka et al., 1984). Alternate processing of the prepro 
ANP in the kidney produces a 32 amino acid peptide known as 
urodilatin. Urodilatin is secreted into the lumen of the distal nephron 
(medullary collecting duct) where it is believed to be involved in 
regulation of sodium and water absorption in the kidney (Forssmann et 
al., 1998; Kuhn, 2005). Physiologically plasma ANP is markedly 
increased in response to pressure or volume overload or in 
pathological states such as heart failure or ventricular hypertrophy. 
However the plasma half life is rather short, averaging less than 3 
minutes which indicates that the release of ANP serves to counteract 
the effect of acute pressure or volume overload (Lang et al., 1985; 
Ruskoaho, 1992).  
 
Figure 2. Synthesis of natriuretic peptides and prohormones  
 
     
  Adapted from Koller and Goeddel 1992 
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Human BNP is produced as a 132 amino acid residue preproBNP 
that is subsequently cleaved to a 108 amino acid prohormone. 
Additional cleavage yields the 32 amino acid active hormone and an 
inactive 76 amino acid amino terminal (NT) fragment sometimes 
known as NT-proBNP (Saito et al., 1989; Seilhamer et al., 1989; 
Sudoh et al., 1988).  Ventricular BNP is not stored in granules in the 
myocytes, instead BNP production is regulated at the transcription 
level by various stimuli, the main stimulus for BNP synthesis is stretch 
of the ventricular wall by volume and/or pressure overload (Grépin et 
al., 1994; Thuerauf et al., 1994). Even though the BNP gene is located 
in tandem with the ANP gene; BNP expression doesn’t always parallel 
ANP gene expression. The response of the BNP gene is quicker than 
that of ANP suggesting a more acute and sustained role for BNP in 
response to a volume overload. Increase in BNP mRNA is detected 
within one hour of increased ventricular wall tension induced by 
increased venous volume or acute myocardial infarction (Hama et al., 
1995; Nakagawa et al., 1995). BNP has a much longer half-life (than 
ANP) of about 20 minutes (Espiner et al., 1995) and  with sustained 
cardiac stress; as in the case of heart failure, BNP mRNA levels have 
been shown to remain increased (Tokola et al., 2001). BNP secretion 
takes two forms, constitutive, where the BNP is secreted as fast as it is 
being formed and a regulated pathway where the BNP is stored in 
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granules prior to being secreted (Kelly, 1985). Ventricular myocytes 
shift between the two pathways depending on the stimulus, the 
constitutive secretion being called upon when there is acute need for 
BNP secretion and the regulated pathways operating when there is a 
sustained myocardial stress such as chronic heart failure (Bloch et al., 
1986; Kelly, 1985). 
CNP is mainly expressed in the brain, chondrocytes and 
endothelial tissue. Myocardial tissue has a much smaller amount of 
CNP than ANP or BNP and CNP is not stored in granules (Yandle, 
1994). In humans, proCNP contains 103 amino acid residues and it is 
cleaved to a 53 amino acid CNP in the brain, the heart and endothelial 
tissue. Further cleavage yields a 22 amino acid peptide which is the 
predominantly circulating form of CNP (Stingo et al., 1992; Totsune et 
al., 1994; Wu et al., 2003). While CNP 53 is believed to be 
predominantly a neurotransmitter, it is also involved in bone and 
cartilage growth; CNP 22 is mainly involved in autocrine and paracrine 
regulation of vascular tone (D'Souza et al., 2004). CNP has less effect 
on diuresis and natriuresis than ANP or BNP and a more potent effect 
on smooth muscle relaxation, it is thus believed to be mainly involved 
in the regulation of coronary vascular tone in the heart (Clavell et al., 
1993; Komatsu et al., 1992; Sudoh et al., 1990). 
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Natriuretic Peptide Receptors 
The natriuretic peptide receptors are members of the 
transmembrane guanylyl cyclase family of enzymes that are widely 
distributed in human and animal tissues. There are at least seven 
different guanylyl cyclase enzymes identified so far (Anand-Srivastava 
& Trachte, 1993; Garbers et al., 2006). Natriuretic peptide receptor 
(NPR) types A and B (NPR-A and NPR-B) are structurally similar and 
exist as homodimers or homotetramers in intact mammalian cells 
(Chinkers & Wilson, 1992; Iwata et al., 1991; Katafuchi et al., 1994). 
The receptor consists of an extra cellular ligand-binding domain, a 
membrane spanning domain and intracellular kinase-like and guanylyl 
cyclase domains (Nagase et al., 1997; Potter, 2005). Both ANP and 
BNP bind to NPR-A although ANP is known to bind with at least 10 
times more affinity to NPR-A (Kambayashi et al., 1990; Nakao et al., 
1991). NPR-B has similar structure to NPR-A, but selectively binds to 
CNP. Natriuretic peptide receptor type-C (NPR-C) has a short 
intracellular sequence that doesn’t have a guanylyl cyclase domain. 
 
 
 
 
 
 
 
 
 
 
Figure 3. Schematic representation of the natriuretic  
               
    peptide receptors 
 
 
 
 
 
                   Adapted from Potter et al., 2006 
 
Ligand binding to the receptor leads to the activation of the 
guanylyl cyclase and results in a conformational change. The C-
terminal guanylyl cyclase then comes into a tight association that 
leads to conversion of guanosine triphospate (GTP) to 3´5´- cyclic 
guanosine monophosphate (cGMP) (Chinkers & Wilson, 1992; Foster et 
al., 1999).  The ATP binding site in the kinase homology domain (KHD) 
is believed to be essential for ligand-induced signal transduction and 
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deletion of the KHD depresses the guanylyl cyclase catalytic region 
(Chinkers & Garbers, 1989). Phosphorylation of amino acid residues in 
the KHD of the receptor is essential for normal function and 
dephosphorylation appears to be one method of the natriuretic peptide 
receptor desensitization (Potter & Garbers, 1992; Potter & Hunter, 
1998).  
 
 
Figure. 4. A model for natriuretic peptide receptor activation  
 
 
 
 
Adapted from Silberbach and Roberts 2001 
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The end result of these mechanisms of receptor activation is 
increased concentration of intracellular cGMP; cGMP in turn exerts its 
physiological effects by binding to one of three cGMP binding proteins. 
cGMP dependent protein kinases (PKG), cGMP binding 
phosphodiesterases (PDE) and cyclic nucleotide gated ion channels 
(Pfeifer et al., 1996; Rybalkin et al., 2003; Smolenski et al., 1998).  
As mentioned earlier, natriuretic peptide receptor type-C (NPR-
C) has a short intracellular sequence that doesn’t have a guanylyl 
cyclase domain. The major role of NPR-C was initially believed to be as 
a clearance receptor and regulation of the plasma concentration of ANP 
and BNP through receptor mediated internalization and degradation 
(Matsukawa et al., 1999). However recent evidence suggests that 
NPR-C is involved in signaling that leads to reduction of adenylyl 
cyclase activity through activation of inhibitory G protein (Gi) (Anand-
Srivastava & Trachte, 1993; Rose & Giles, 2007).  
The natriuretic peptides are cleared from the circulation by three 
mechanisms. Endocystosis and degradation by coupling with NPR-C, 
enzymatic cleavage by neutral endopetidases and by glomerular 
filtration and excretion in the urine (Boerrigter & Burnett, 2004; Freda 
& Francis, 2006).  
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Tissue Distribution of Natriuretic Peptides and their Receptors 
The atrial and ventricular cardiomyocytes are the main sites of 
production and storage of ANP and BNP, respectively. This was 
confirmed through seminal experiments that showed that atrial 
appendectomy resulted in marked reduction of both the plasma levels 
of  ANP and the diuretic and natriuretic effect seen in response to a 
volume load with isotonic saline (Veress & Sonnenberg, 1984; 
Villarreal et al., 1986). Nevertheless, ANP and BNP mRNA have been 
detected in several non-cardiac tissues including the adrenal glands, 
the kidneys, lung, the gonads, lymphoid tissue and the gut (Gerbes et 
al., 1994; Gower et al., 1994; Gower et al., 2003; Li et al., 2006; 
Nguyen et al., 1990; Sharkey et al., 1991; Vollmar, 1990).  Natriuretic 
peptide receptors have also been detected in the gastrointestinal (GI) 
tract of both non-mammalian and mammalian species including 
humans (Gower & Skvorak, 1997; Li & Goy, 1993; Lowe et al., 1989; 
Ohyama et al., 1992; Schulz et al., 1998). 
 
Physiological Effects of the Natriuretic Peptides 
Vascular relaxation is one of the most important physiological 
actions of the natriuretic peptides. Binding of cGMP to PKG is known to 
regulate ion channels in vascular smooth muscle cells with a cascade 
of molecular events that culminate in a lower concentration of 
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intracellular calcium. These effects include reduction of calcium influx, 
increase of calcium efflux and promotion of calcium sequestration in 
sarcoplasmic reticulum (Tamaoki et al., 1997).  Reduced vascular tone 
and vasodilatation in turn results in lower total peripheral vascular 
resistance which has important physiological benefit on the 
cardiovascular system; especially in the face of cardiac ischemia or 
volume overload. Such vascular relaxation and vasodilatation will also 
result in reduced pressure in the renal afferent arterioles thereby 
increasing glomerular filtration, promoting diuresis and natriuresis. In 
addition to these effects on vascular smooth muscle cells, the direct 
effect of ANP and BNP on renal tubules and mesangial cells as well as 
inhibition of the renin angiotensin aldosterone (RAAS) system results 
in decreased sodium absorption from the renal tubules (Lohmeier et 
al., 1995; Zeidel, 1993).  
ANP and BNP are also known to decrease sympathetic outflow 
and catecholamine release from peripheral sympathetic neurons which 
benefits the cardiovascular system since it leads to lower blood 
pressure, decreased heart rate and natriuresis (Levin et al., 1988). 
Further support for the importance of the natriuretic peptides in blood 
pressure and blood volume regulation comes from data showing that 
NPR-A transgenic mice show chronic hypertension and ventricular 
hypertrophy (John et al., 1995). NPR-A transgenic mice were recently 
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shown to have an upregulation of the angiotensin converting enzyme 
(ACE) and angiotensin II type 1a receptor (AT1) mRNA by up to four-
fold signifying the importance of the natriuretic peptides in 
counteracting the effect of the renin angiotensin aldosterone (RAS) 
system (Vellaichamy et al., 2007). It is also shown that NPR-A 
knockout mice exhibit dysregulation of matrix metalloproteinases and 
tissue inhibitors of metalloproteinases; enzymes involved in the 
regulation of collagen synthesis and organization of myocardial fibrils 
(Li et al., 2000; Spinale, 2002). As a result NPR-A knockout mice show 
increased tendency towards myocardial fibrosis, hypertrophy and 
eventually heart failure that leads to premature death as compared to 
the wild type mice.   
 
Gastrointestinal Effects of Natriuretic Peptides 
Natriuretic peptides are known to have several effects on 
contractile and absorptive functions in the GI tract. ANP has been 
shown to inhibit intestinal sodium and water absorption in teleost and 
mammalian intestines (Barros et al., 1990; Matsushita et al., 1991; 
O'Grady et al., 1985). A decrease in jejunal water absorption in 
response to intravascular volume overload was also shown in rats. 
Such a decrease in transjejunal water absorption was absent in rats 
that underwent right atrial appendectomy and this effect returned 
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when ANP was exogenously administered (Pettersson & Johnsson, 
1989).  Intravenous administration of BNP and CNP has also been 
shown to decrease jejunal electrolyte and water absorption in dogs 
(Morita et al., 1992). Earlier investigations have also shown that 
injection of either ANP or BNP into the cerebral ventricles inhibits thirst 
induced by water deprivation or angiotensin (Antunes-Rodrigues et al., 
1985; Itoh et al., 1988; Zhu & Herbert, 1996). Furthermore, ANP and 
BNP have been shown to have an indirect effect on uptake and 
excretion of sodium and water through inhibition of vasopressin and 
aldoseterone secretion (Januszewicz et al., 1986; Nguyen et al., 
1989).  
The effect of natriuretic peptides on contractility of GI smooth 
muscle has been documented beginning with the early discovery of 
these peptides and their receptors in the GI tract (Scott & Maric, 
1991). Subsequent studies have confirmed these findings showing that 
ANP, BNP and CNP all inhibit contractility of isolated gastric and 
intestinal smooth muscle cells from different species including 
humans(GuoCui et al., 2003; GuoJin et al., 2003; Yasuda et al., 
2000).   
Apart from the traditional ‘cardiac’ natriuretic peptides ANP, BNP, 
and CNP; the GI tract is also known to be a source of two peptides 
with structures very similar to the natriuretic peptides. Guanylin and 
 19
uroguanylin were first isolated from rat intestine and opossum urine 
and later found to be widely distributed in non-mammalian and 
mammalian species including humans (Beltowski, 2001; Date et al., 
1998). In humans, uroguanylin is mainly expressed in the 
enterochromaaffin (EC) cells of the duodenum (where ANP is also 
expressed), whereas  guanylin is expressed in the jejunum and the 
colon (Beltowski, 2001; Li et al., 2006).  Uroguanylin is secreted in 
response to oral salt load and the circulating hormone is known to 
mediate sodium balance in the post-prandial state by increasing renal 
excretion of sodium and potassium while the luminally secreted 
hormone leads to increased chloride and bicarbonate secretion in to 
the lumen of the intestine (Beltowski, 2001; Forte et al., 1996). 
Uroguanylin and guanylin mRNA are detectable in the atrial and 
ventricular myocardium and interestingly, plasma levels of guanylin 
and uroguanylin are increased during heart failure and renal failure 
(Beltowski, 2001; Forte et al., 1996).  Both guanylin and uroguanylin 
receptors are membrane bound guanylyl cyclase enzymes and 
activation of these receptors leads to increased intracellular cGMP 
(Carrithers et al., 1999; Forte et al., 1996; Forte et al., 1999). Both 
synergistic and antagonistic interaction between ANP and BNP on one 
hand and uroguanylin and guanylin on the other have been shown and 
there has been some suggestion that this evidence points to a 
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probable regulatory link between the kidney and the GI tract in the 
process of sodium and water balance (Santos-Neto et al., 2006).   
Taken together, the remarkable genetic conservation of the 
natriuretic peptides, the stimuli for their release and their effect on 
sodium and water uptake is strong evidence that they serve crucial 
physiological functions that conferred survival benefit earlier in 
evolutionary times and have since evolved to be important conveyers 
of signals among the various organ systems involved in cardiovascular 
homeostasis.  
While the cardio-renal link is now sufficiently well established, 
there have been very few studies conducted to assess the functional 
significance of the effect of natriuretic peptides on the GI tract and 
how this all fits in the bigger scheme of volume regulation. The early 
observations on the effect of natriuretic peptides as well as recent 
evidence showing the presence and role of a possible ‘intestinal’ 
natriuretic peptide system raise several intriguing questions. If the 
heart sends humoral signals to the kidney to decrease sodium 
absorption, shouldn’t it also use the same signals to limit sodium and 
water absorption from the GI tract? GI symptoms such as nausea, 
indigestion and malabsorption are frequent clinical findings in the face 
of acute heart attack or chronic heart failure, states where BNP levels 
are elevated. Could BNP be responsible for some of these symptoms? 
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If so, could there be potential targets of therapy for heart failure in the 
GI tract?  
Our studies will provide evidence that the effect of natriuretic 
peptides on gastric and intestinal smooth muscle cell contractility has a 
functional dimension. By directly testing the effect of ANP, BNP and 
CNP on gastric contractility, gastric emptying and absorption we show 
that these peptides do decrease gastric emptying and absorption. 
Moreover BNP, a peptide with increasing clinical utility, is shown here 
to cause decreased gastric emptying and intestinal absorption 
following acute myocardial injury using a whole animal cryo induced 
acute MI model. While our data suggests that these effects may be 
mediated by NPR-A, we also show data that suggests a more direct 
effect on absorptive structures at the level of intestinal microvilli. 
Further characterization of the signals involved in these functions not 
only adds a new dimension to cardiovascular research but could also 
lead to identification of new therapeutic targets for the treatment of 
heart failure.  
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CHAPTER TWO 
 
MATERIALS AND METHODS 
 
 
Measurement of Gastric Contractility and Intragastric Pressure  
 
These protocols were approved by the University of South Florida 
Institutional Animal Care and Use Committee.  
 
Experimental Animals 
NPR-A Knockout (KO) mice were obtained from our resident 
colony that was founded with pathogen-free breeding pairs and were 
genetically monitored by PCR of tail-snip DNA. The generation of NPR-
A knockout mice has previously been described in detail (Lopez et al., 
1995). Wild type (C57BL/6) mice were purchased from commercial 
sources. The wild type (WT) mice were all males with ages ranging 
from 8 to 12 weeks and weight ranging from 18-26 grams at the time 
of the experiment. The NPR-A KO mice ranged from 10 to 32 weeks in 
age and 24-38 grams in weight at the time of the experiment, with 
equal number of male and female KO mice in the experiment and 
vehicle group. The parental strain of the knockout mice was C57BL/6. 
 23
Surgical Preparation  
In order to objectively determine the effect of natriuretic 
peptides on gastric contractility, a method of measuring intragastric 
pressure before and after peptide injection was developed as follows.  
The mice were anesthetized with sodium pentobarbital (0.9 mg/10 gm 
body weight) given intraperitoneally (ip) and supplemental doses of 
0.5 mg given ip as needed. The mice were then placed on a 
temperature controlled surgical table and a tracheotomy was 
performed using a 20 ga. Luer-stub adapter. The right jugular vein 
was catheterized with polyethylene (PE)10 tubing for injections and 
infusions and the right carotid was catheterized with a 5 cm piece of 
PE tubing (o.d. 0.012”, i.d. 0.006”: Braintree Scientific, Inc.) attached 
to a 12-18” segment of PE 50 tubing for arterial blood pressure 
measurements.  A 10 mm left sub-costal skin incision was made to 
access the stomach. A 3 mm vertical incision of the stomach fundus 
was made with cautery carefully choosing a site that has minimal or no 
visible blood vessels. A 2-3 mm latex balloon fitted with PE tubing and 
primed with saline was inserted into the stomach. The balloon was 
then minimally distended by adding 20-25 µl of saline and attached to 
a standard pressure transducer (Gould/Statham DB25). The 
intragastric catheter was held in place by the minimal distension of the 
balloon and suturing the stomach incision was not necessary. The skin 
 24
incision was closed with 1-2 interrupted surgical sutures. Following 
these surgical preparations, the mice received a 100 µl bolus of 0.9% 
saline intravenously (iv) via the jugular catheter and then allowed a 
one hour equilibration period while being infused with 0.9 % saline iv 
at 5 µl/minute. The saline bolus and infusion were administered to 
compensate for blood loss associated with the surgical procedure and 
maintenance fluid requirement. Arterial blood pressure, heart rate and 
intragastric pressure were monitored continuously via the carotid and 
intragastric catheters and recorded on a data acquisition system 
(DATAQ Instruments, Akron, OH).  
The change in intragastric pressure was measured as the 
difference between the peak and baseline pressure. The 
measurements were taken for three 30 minute periods. The basal 
gastric pressure was measured from 30 to 0 minutes before injection.  
Post injection period was from 10 to 40 minutes after injection to 
correspond with the peak plasma level of the peptides and the 
recovery period was from 90 to 120 minutes after injection 
corresponding to the period later than 5 peptide half-lives (12). The 
changes in intragastric pressure during each of the three periods were 
averaged for each mouse and the differences in intragastric pressure 
between the experimental and vehicle groups during the three periods 
were compared using a one way ANOVA with Fisher’s least significant 
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difference test (LSD) used as a post hoc test. A “p” value of <0.05 was 
considered the criteria for statistical significance.  
 
Positive and Negative Controls 
 Gherelin, a hormone with known prokinetic gastrointestinal  
effect in rodents, was used as a positive control to ascertain that the 
waves of contraction we observed and recorded were indeed changes 
in gastric motility (Depoortere et al., 2005). Gherelin (Rat, Phoenix 
pharmaceuticals, C# 031-31, Lot # 423341) was administered at a 
dose of 50 µg/kg body weight in 100 µl of vehicle iv, a dose previously 
established to increase gastric motility in rodents.  
The vehicle was used as a negative control. The vehicle 
consisted of modified Krebs-Hensledt bicarbonate buffer equilibrated 
final PH = 7.4, dissolved in the order shown in table 1. 
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Table 1. Composition of modified Kreb’s solution (g/l) 
 
CaCl2 0.220g 
MgSO4 0.144g 
KCl 0.224g 
KH2PO4 0.163g 
NaCl 6.72g 
NaHCO3 2.1g 
Glucose 1g 
Albumin 1g 
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Table 2. Millimolar concentration of modified Kreb’s solution 
 
Na+ 140 
K+ 4.2 
Ca2+ 1.5 
Cl- 123 
Mg2+ 1.2 
HCO3 25 
H2PO4 1.2 
SO4 1.2 
Glucose 2.5 
Albumin 
(BSA fraction V) 
0.1% 
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 Blood Pressure Measurement 
 Mean arterial pressure was continuously monitored using an 
intra-carotid catheter and recorded. Average blood pressure was 
measured for the same three periods as for the gastric pressure 
measurement. Pre vs. post peptide injection blood pressures were 
compared to ascertain that our findings were not confounded by 
differences in blood pressure.  
Measurement of Gastric Emptying  
Conscious WT and NPR-A KO mice (n = 5 in each group) were 
given BNP at dose of 10 ng/g through the tail vein dissolved in 100 µl 
of vehicle (modified Krebs solution) or the vehicle alone and 
immediately gavaged with 0.1 ml of 0.5 Mmol 70 kDa fluorescein-
isothiocyanate (FITC)-dextran. The 70 kDa FITC-dextran is known to 
be non-diffusible across intestinal membrane thus suitable for 
measurement of emptying (Thorball, 1981). Thirty minutes after the 
gavage meal, the animals were euthanized and the stomach was 
separated and the intestine divided into 8 equal segments, each 
flushed with 3 ml of PBS and centrifuged for 10 minutes. Fluorescence 
of the supernatant fluid was measured and the percent gastric 
emptying rate was compared in BNP treated vs. control for both WT 
and NPR-A KO mice. This method of evaluating gastric emptying has 
been previously established (Aube et al., 2006). 
 29
Measurement of Absorption  
Conscious WT & NPR-A KO mice (n = 5 in each group) were 
given 10 ng/g of BNP through the tail vein dissolved in 100 µl of 
vehicle (modified Krebs solution) or the vehicle alone. The mice were 
then gavaged with 0.01 ml/g of a solution containing 22 mg/ml of 4 
kDa FITC-dextran. Blood was collected via cardiac puncture under 
pentobarbital anesthesia. Fluorescence was quantified using relative 
fluorescence units in the plasma. The plasma fluorescence measured 1 
hour after gavage feeding in WT and NPR-A KO mice was compared for 
BNP treated vs. control. Similar comparisons were made for the 
subsequent experiments between sham vs. Mi in both WT and NPR-A 
KO mice. The group differences were analyzed using a t-test with 
p<0.05 considered the significant level for statistical difference. This 
method of evaluating gastric absorption has been previously 
established (Aube et al., 2006). 
We also compared the fluorescence of a 50 µl plasma sample 
taken 1 hour after iv administration of 100 µl of 0.5 mmol 4kDa FITC-
dextran in BNP treated vs. vehicle WT mice. The purpose of this test 
was to rule out the possibility that the changes in plasma fluorescence 
were produced by other actions of BNP such as increased excretion, 
redistribution or metabolism of the dextran as this effect of BNP has 
been previously established (Huxley et al., 1987).  
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The concentration of fluorescein was determined using a 
fluorimeter (FLUOstar Galaxy, BMG Labtechnologies) with an excitation 
wavelength at 485 nm and an emission wavelength of 520 nm using 
serially diluted samples of the marker as standard. 
 
 
Table 3. Peptides used in this study  
 
ANP Rat ANP, Sigma, P # A8208 
BNP Rat BNP-32, Phoenix Pharmaceuticals, 011-14, 
 Lot # 421752 
CNP Rat 32-53, Bachem, P # H-1296, Lot # B00656 
c-ANF 4-23 Rat, Phoenix Pharmaceuticals 
Gherelin Rat, Phoenix Pharmaceuticals, C # 031-31, Lot # 423341 
 
 In the initial experiments, the peptides were administered 
intravenously at 10 ng/g body weight. This dose was chosen to raise 
and sustain the plasma levels above 500 pg/ml; a level that is 
consistent with a greater than 90% likelihood of heart failure (for BNP) 
in humans (Maisel & Mehra, 2005).  For subsequent dose response 
experiments we administered BNP at 1, 5, 10 and 100 ng/g body 
weight iv.  
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Induction of Myocardial Ischemia (Myocardial Injury) 
 
Wild-type and NPR-A knockout mice were anesthetized with 2-
3% isoflurane-oxygen flow at 500ml/minute. A 2 mm incision was 
made through the skin, just distal to the 4th and 5th intercostal space.  
Blunt dissection through all thoracic musculature, using a fine-tipped 
instrument was performed to accommodate passage of a probe 
induction catheter (PIC).  Using digital pressure, the distal tip of the 
PIC (catheter cap in place) was flattened as much as possible (to aid in 
atraumatic insertion), and the PIC was then passed through the 
muscle wall.  Prior to removing the cap, the operator pinched the 
proximal tip of the PIC shut (to aid in the prevention of 
pneumothorax).  The oxygen flow was then turned up to 2 L/min. The 
liquid-nitrogen-cooled probe was then quickly threaded through the 
PIC, to the full length of the PIC.  If needed, the PIC was then gently 
repositioned so the bevel and the cooled probe were in direct contact 
with the left ventricle of the heart.  Correct placement of the probe, 
with subsequent cardiac thermal injury, was confirmed as the super 
cooled probe "grabbed" the warmer tissue of the heart, and remained 
affixed until the probe had warmed enough for release.  After passive 
release, the probe and PIC, as one unit, were quickly withdrawn and 
the ribs were then immediately brought into apposition.  A pre-loaded 
1/2 cc syringe of tissue glue (VetBond™) was then used for closure. 
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The experiment to study emptying and absorption were performed at 1 
and 2 weeks after this surgical procedure (cryo induced myocardial 
injury/infarction). 
 
Plasma BNP Measurement by Radioimmunoassay 
 
Plasma BNP levels were measured by radioimmunoassay (RIA). 
(Peninsula Laboratories, 5-2104 RIAS 9085). The assay is based upon 
the competition of 125I-labeled peptide and unlabeled peptide 
(unknown sample) binding to the limited quantity of antibodies specific 
for peptide in each reaction mixture. As the quantity of peptide in the 
unknown sample in the reaction increases, the amount of 125I-bound 
peptide able to bind to the antibody is decreased. By measuring the 
amount of 125I- bound peptide as a function of the concentration of the 
peptide in standard reaction mixtures, a “standard curve” is 
constructed from which the concentration of peptide in the unknown 
sample can be determined. 
The summary of the assay protocol is as follows: 
1- A 100 µl of unknown sample is pipetted in to duplicates glass  
      
 test tubes 
 
2- 100 µl primary antibody is added to unknown samples,  
      
vortexed, and incubated overnight at 4°C. 
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3- 100 µl of the I 125 labeled peptide is added and incubated  
      
overnight at 4°C. 
 
4- Goat rabbit antiserum and normal rabbit serum is added and  
     
   vortexed at 4°C and incubated for 90 minutes 
 
5- 500 µl of RIA buffer is added, vortexed and centrifuged at  
      
1700 x g for 20 minutes 
 
6-The supernatant is aspirated off except in the total counts  
   
tube 
 
7- Use gamma counter to count the level of radioactivity 
 
8- The data obtained from the gamma counter is analyzed using 
     
the program Assayzap, Biosoft, GB, United Kingdom. 
 
The detailed assay protocol is found in the product insert for the assay 
kit (Phoenix pharmaceuticals, C# RK-011-17)  
The kit we used has a cross reactivity of 41% with the mouse 
BNP and total binding of 46%; calculations were made accordingly. 
The detection range for this kit was 10-128 pg/ml. 
 
Immunostaining for Non-Muscle Myosins 
  Two WT mice were given a bolus of BNP at 10 ng/g body weight 
in 100 µl of modified Kreb’s solution followed by infusion of BNP at 1 
ng/g for 30 minutes. One WT mouse was given 100 µl of vehicle and 
given an infusion of vehicle for 30 minutes  
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1- The animals were then euthanized and intestinal tissue collected 
and sectioned into duodenum, jejunum, ileum and colon 
following anatomical demarcations. 
2- The tissue is fixed in 4% paraformaldehyde over-night at 4°C. 
3- The next morning the tissue is washed with phosphate buffered 
saline (PBS) for 15 minutes twice at room temperature with 
gentle rocking. 
4- After the wash, the tissue is dehydrated and permeabilized as 
follows. Tissue is placed in ascending concentration of 30, 50 
and 70 % methanol each for 15 minutes. Then the tissue is 
placed in a solution composed of 100 % methanol: DMSO: 30% 
H2O2 made at a ratio of 4:1:1. The tissue is left in this solution 
overnight at 4°C .   
5- The next morning the tissue is washed in 70 % methanol for 30 
minutes at room temperature with rocking.  
6- Rehydration is accomplished by serially placing the tissue in 70 
% methanol/PBS for 30 minutes with rocking, then 50 % of 
methanol/PBS with rocking, then 1 ml of PBS for 30 minutes 
with rocking, 1 ml of PBSMT (PBS, milk, Tween 20) 30 minutes 
with rocking twice.  
7- The tissue is then incubated overnight with 1 ml of primary 
antibody diluted in PBSMT (1:250) with rocking at 4 °C.  
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8- The next morning the tissue is rinsed with PBSMT 2x with 1 ml 
for 1 hour at 4°C, 4 x in 1 ml for 1 hour each at room 
temperature. 
9- Next the tissue is incubated overnight with 1 ml of the 
Secondary antibody diluted in PBSMT (1:250) at 4°C while 
rocking.  
10- Next morning the tissue is washed as above with PBSMT 
11- Next tissue is rinsed with PBT (PBS and Tween -20 equal 
concentration). 
12- Post fixing in 4 % paraformaldehyde in PBS at 4 ° C overnight. 
13- Dehydration in the following sequence, 1 ml of PBT quick rinse, 1 
ml PBT for 30 minutes at room temperature, 1 ml 50 % 
methanol for 30 minutes, 1 ml of 70 % methanol for 30 minutes 
at room temperature; 1 ml of 100 % methanol 30 minutes at 
room temperature twice.  
14- Plastic embedding is achieved by transferring the tissue from 
100 % methanol to araldite embedding medium and kept in 
medium for 3 hours. The tissue is then transferred into a fresh 
embedding medium into a mold on araldite rafts and the mold is 
kept overnight in 60° C oven to allow the araldite to harden.  
 
 36
15- The hardened plastic embedded tissue is then trimmed and 
sectioned using a microtome at 1-3 µm thickness. The sections 
pass automatically into water, the sections are transferred onto 
a slide and allowed to dry for 5-10 minutes on the surface of a 
hot plate. The first and last section are placed on one side and 
stained with toluidine blue to guide orientation.  
 
Details of the above technique are found in (Linask & Tsuda, 2000). 
 
Statistical Methods 
We used a one way analysis of variance (ANOVA) to compare the 
average intragastric pressure at baseline, immediately after and later 
than five peptide half-lives after peptide injections. Fisher’s least 
significant difference (LSD) test is used as a post hoc test. 
Two sample t-tests were used to compare the measures of gastric 
emptying and absorption between peptide treated vs. vehicle treated 
mice. Specifically percent gastric emptying between treated vs. vehicle 
and average relative fluorescence units between the peptide treated 
vs. vehicle groups were tested using a two sample t-test. 
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CHAPTER THREE 
 
 
THE EFFECT OF NATRIURETIC PEPTIDES ON INTRAGASTRIC 
 
PRESSURE, GASTRIC EMPTYING AND ABSOPRTION 
 
 
INTRODUCTION 
 
 
 Measurement of gastric pressure using an intragastric balloon 
(manometry) offers the most direct way to quantify pressure changes 
inside the stomach (Malagelada & Stanghellini, 1985; Mearin & 
Malagelada, 1993). Other factors being constant, the measured gastric 
pressure is directly proportional to the force of contraction of the 
stomach wall (Mearin & Malagelada, 1993); therefore quantifying and 
comparing the rate of change in pressure between experimental 
groups yields a reliable and objective measure of gastric contractility.  
However, due to the inherent variability of baseline pressure among 
different animals, we further standardized the measurement by using 
the difference between the baseline and peak of the gastric contraction 
wave in our analysis. This makes our measurement less prone to 
variability and a more objective way to compare differences in 
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pressure between or among different groups of animals in these 
experiments.  
Our measurements of gastric emptying and absorption were 
designed to be as close to the physiological state as possible. We used 
gavage feeding of fluorescence labeled dextran and let the mice roam 
freely for 30 minutes, following which the surgery was performed and 
measurement taken. The 70 kDa FITC-dextran was shown to be a 
valid measure of emptying in prior studies as was the 4 kDa FITC 
dextran for gastrointetsinal absorption (Aube et al., 2006; Thorball, 
1981). Since there is a theoretic possibility that there is a potential 
confounding by the action of BNP on arterial permeability and 
distribution of the dextran to the third space (rather than GI tract 
permeability or absorption) we measured and compared plasma 
fluorescence after intravenous injection of 4 kDa FITC-dextran in BNP 
treated and control animals. This avoids the potential confounding and 
validates our measurement.  
 
 
 
 
 
 
 
 
 
 
 
 
RESULTS 
  
  
 
Intragastric Pressure and Gastric Contractility  
 
 
A typical intragastric pressure wave pattern is shown in figure 5; 
gastric contraction frequency averaged 3-7 times per minute ranging 
from 0.5 to 10 mmHg in amplitude.  
 
Figure 5. Typical pressure wave pattern of a basal gastric                         
                  contraction 
 
 
A recording of a basal pressure pattern in windaq file is shown above. 
Division width = 4 seconds and division height =1 mmHg. Recording 
shown is a 10x compression (approximately 3 minutes) view of an 
actual experiment  
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Figure 6. Simultaneous recording of blood pressure 
                and intragastric pressure 
 
 
Two channel recording in our data acquisition system - windaq, Top 
panel shows blood pressure and bottom panel shows intragastric 
pressure. Note; division heights are 6.25 mmHg in top panel and 1 
mmHg in bottom panel. Division width is 4 seconds in both channels. 
Recording shown is 10x compression of an actual experiment. 
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The prokinetic agent gherelin was used to ascertain that these 
recordings from the intragastric balloon corresponded to changes in 
gastric motility. Administration of gherelin resulted in a marked and 
significant increase in intragastric balloon pressure, validating that the 
contraction waves recorded are that of changes in gastric contractility.  
Gherelin was administered in three experiments and a typical response 
is shown in figure 7.  
 
Figure 7. The effect of intravenous administration of Gherelin 
              on intragastric pressure 
 
 
Davison width = 8 seconds and division height = 1mmHg. 
Arrow indicates point of injection of gherelin 
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Figure 8. Three individual experiments showing intragastric   
pressure after a 10 ng/g iv bolus of ANP, BNP and CNP.  
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C 
N 
P 
Division height = 1mmHg.  Division width = 300 seconds 
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As shown in figure 8, intragastric pressure was decreased after 
injection of any of the three natriuretic peptides, ANP, BNP or CNP and 
the pressure gradually returned towards the baseline values.  
 
Figure 9.  Typical recording of post peptide injection gastric 
 
                  contraction wave pattern         
      
 
 
Gastric pressure was attenuated after injection of BNP without 
significant change in frequency of contraction. Also seen is a slight dip 
in mean arterial pressure following BNP injection. Arrow indicates point 
of injection. ‘Decompressed’ view, image shown is approximately 1 
minute. A similar effect was observed for ANP and CNP.  
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Figure 10. The effect of C-ANP4-23 on gastric pressure 
 
 
 
Individual experiment showing no change in gastric pressure or blood 
pressure when the specific NPR-C ligand cANP4-23 was injected in to 
wild type mice at 10 ng/g body weight iv.  
Division width =80 seconds  
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Figure 11.  BNP did not change gastric pressure in NPR-A knock 
out mice 
 
 
 
 
NPR-A knock out mice did not show decreased intragastric pressure 
with any of the natriuretic peptides. Here BNP was administered at 10 
ng/g body weight iv.  
We quantified the change in intragastric pressure by averaging the 
difference between the peak and baseline gastric pressures for three 
thirty minute periods; before, immediately after and later than 5 
peptide half-lives after peptide injection.  
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Figure 12. Determination of baseline and peak intragastric 
pressure before and after peptide injection 
 
 
 
 
 
Since each experimental animal had different baselines; comparing the 
difference between baseline and peak (i.e., the change in amplitude of 
the gastric contraction wave) was found to be more precise and 
reliably comparable among different experimental animals. The basal 
pressure was defined as the lowest pressure immediately before a 
peak and the peak was determined by moving the cursor and 
recording the highest point of the peak pressure. 
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Figure 13 (below) shows the pooled data on comparison of the 
average gastric pressure before peptide injection (Basal), immediately 
following peptide injection and later than 5 BNP half-lives (Recovery) 
vs. vehicle. As shown, BNP significantly decreased intragastric 
pressure from a basal value of 2.26 ± 0.29 mmHg to 1.44 ± 0.11 
mmHg and gastric pressure returned to 2.08 ± 0.17 mmHg when 
measured later than 5 BNP half-lives (n=5, p<0.05, ANOVA, Fisher’s 
LSD test). Similar and statistically significant reduction of gastric 
pressure was obtained for ANP and CNP (Figures 14 and 15). ANP 
significantly decreased gastric pressure from a basal value of 2.11 ± 
0.3 mmHg to 0.7 ± 0.25 mmHg and CNP decreased gastric pressure 
from a basal value of 1.91 ± 0.3 mmHg to 0.85 ± 0.24 mmHg. 
Average gastric contractions per minute were 4.4 ± 0.7, 3.1 ± 0.4 and 
4.3 ± 0.5 for periods of BNP injection compared to 5.3 ± 1.2, 4.2 ± 
0.6 and 4.3 ± 0.5 for the vehicle group (all p>0.05, ANOVA).There 
was no difference in gastric pressure in BNP treated vs. vehicle treated 
NPR-A KO mice.  
 
 
 
 
 
 
 
 
 
Figure 13. Mean reduction in intragastric pressure following  
 
                 intravenous BNP injection 
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Mean reduction in intragastric pressure (measured in mmHg) following 
intravenous BNP 10 ng/g in 100 µl of vehicle vs. 100 µl of vehicle 
injection to WT mice (n = 5 in each group). Intragastric pressure 
measured before (Basal), immediately after (Post Injection) and more 
than 5 peptide half-lives after injection (Recovery) is shown. 
BNP significantly (* = p < 0.05, ANOVA, Fisher’s LSD test) decreased 
intragastric pressure compared to vehicle. Gastric pressure returned 
toward basal levels when measured later than 5 BNP half-lives. 
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  Figure 14. Mean reduction in intragastric pressure following  
 
            intravenous ANP given at a dose of 10 ng/g body weight 
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Mean reduction in intragastric pressure (measured in mmHg) following 
intravenous ANP 10 ng/g in 100 µl of vehicle vs. 100 µl of vehicle 
injection to WT mice (n = 5 in each group). Intragastric pressure 
measured before (Basal), immediately after (Post Injection) and more 
than 5 peptide half-lives after injection (Recovery) is shown. 
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ANP significantly (* = p < 0.05, ANOVA, Fisher’s LSD test) decreased 
intragastric pressure compared to vehicle. Gastric pressure returned 
toward basal levels when measured later than 5 ANP half-lives. 
Figure 15. Mean reduction in intragastric pressure following  
 
           intravenous CNP given at a dose of 10 ng/g body weight 
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Mean reduction in intragastric pressure (measured in mmHg) following 
intravenous CNP 10 ng/g in 100 µl of vehicle vs. 100 µl of vehicle 
injection to WT mice (n = 5 in each group). Intragastric pressure 
measured before (Basal), immediately after (Post Injection) and more 
than 5 peptide half-lives after injection (Recovery) is shown. 
CNP significantly (* = p < 0.05, ANOVA, Fisher’s LSD test) decreased 
intragastric pressure compared to vehicle. Gastric pressure returned 
toward basal levels when measured later than 5 CNP half-lives. 
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Gastric Emptying 
Gastric emptying was measured by gavage feeding a 0.1 ml of 
2.5 mmol 70 kDa FITC labeled dextran to conscious mice immediately 
after a 10 ng/g body weight bolus of BNP. The mice were sacrificed 30 
minutes after gavage and the amount of fluoresce that has emptied 
the stomach as a percent of total fluorescence measured in the entire 
GI tract was calculated and compared between the BNP treated vs. 
vehicle treated mice.  
Figure 16. The effect of BNP on gastric emptying  
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Percent gastric emptying, measured in amount of fluorescence that 
emptied the stomach as a percentage of the total fluorescence 
measured in the entire gastrointestinal tract 30 minutes after gavage 
feeding of 0.01 ml of 2.5 mmol 70 kDa FITC-dextran.  
BNP (10 ng/g iv) significantly decreased gastric emptying in wild 
type mice compared to vehicle (n =5, p < 0.05, t-test,). This effect of 
BNP was absent in NPR-A knockout mice (n = 5, p > 0.05, t-test).  
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Figure 17. Dose dependent reduction of gastric emptying 
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Figure 17 shows percent decrease in gastric emptying as a 
function of BNP dose in WT mice. Measurements were taken 30 
minutes after gavage feeding of 0.01 ml/g of 2.5 mmol FITC-dextran. 
Progressive doses of BNP at 5, 10 and 100 ng/g iv resulted in 
significant reduction of gastric emptying. (p < 0.05, n = 4 in each 
group, ANOVA, Fisher’s LSD test) 
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Absorption 
 To measure absorption we used gavage feeding of 22ml/kg of a 
solution containing 22mg/ml 4 kDa FITC-dextran to conscious mice 
immediately following a 10 ng/g dose of BNP vs. vehicle. The plasma 
fluoresce (taken 1 hour after gavage) was measured and compared 
between the two groups. Plasma fluorescence after iv injection of FITC 
dextran is also measured and shown below to ascertain that the 
difference was not due to distribution rather than absorption.  
 
Figure 18.  The effect of BNP on absorption 
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Absorption measured in relative plasma fluorescence units one hour 
after gavage feeding of 4 kDa FITC-dextran in wild type mice BNP 
treated (10 ng/g iv) vs. vehicle (n = 5, p < 0.05, t-test). No significant 
difference in absorption was observed between BNP vs. vehicle treated 
NPR-A KO mice (p > 0.05). 
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Figure 19. Plasma fluorescence following intravenous  
         
             FITC- dextran, BNP vs. Vehicle 
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Relative fluorescence of a 50µl plasma sample taken 1 hour after 
intravenous administration of 100 µl 0.5mmol 4kDa FITC-dextran is 
shown. BNP treated (10 ng/g iv) vs. vehicle in wild type mice, (p > 
0.05, n = 4 in each groups, t-test). 
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Mean arterial blood pressure was continuously monitored during 
all experiments using an intra-carotid catheter. There was a slight 
reduction of average blood pressure from 62.9 ± 4.7 mmHg prior to 
BNP injection to 59 ± 3.2 mmHg (n=5, p>0.05, ANOVA, Fisher’s LSD 
test). Blood pressure returned to 61.4 ± 5.08 mmHg when measured 
later than 5 peptide half-lives. 
Similar drops in blood pressure were also observed during the 
first few minutes after injection of both ANP and CNP with return of 
blood pressure towards baseline. 
 
Plasma BNP levels averaged 4500 pg/ml and the levels fell to 
725 pg/ml at 30 minutes post injection and to undetectable levels at 
90 minutes post injection.  
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DISCUSSION 
 
These experiments show that the natriuretic peptides tested, 
namely ANP, BNP and CNP all decreases intragastric pressure (gastric 
contractility) in anesthetized mice. Prior studies have shown that 
natriuretic peptides decrease contractility of isolated gastric and 
intestinal smooth muscle cells in vitro (GuoCui et al., 2003; Yasuda et 
al., 2000), this study is the first to show this effect to be true in the 
whole intact animal. Furthermore, the inhibitory effects of the 
natriuretic peptides appears to be dose dependent and mediated 
primarily by NPR-A.  
We further investigated whether this effect on contractility has a 
functional significance in the whole animal. To accomplish this we 
focused the subsequent studies on the effect of BNP on gastric 
emptying and absorption; with its increasing utility in the diagnosis 
and treatment of heart failure, further characterization of an aspect of 
BNP is deemed to be potentially of important translational benefit.  
Our findings confirmed that this effect of BNP on contractility is 
accompanied by significant reduction in gastric emptying and 
gastrointestinal absorption; clearly demonstrating that this inhibitory 
effect on the gastrointestinal tract has functional significance in the 
whole animal. 
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As shown in Figure 19, plasma fluorescence one hour after iv 
administration of 4 kDa FITC-dextran was similar in BNP treated vs. 
vehicle. This finding further strengthens our conclusion that the 
reduced plasma fluorescence in gavage fed and BNP treated mice was 
indeed due to decreased absorption or permeability in the GI tract and 
not due to other known actions of BNP such as increased renal 
excretion or change in vascular redistribution (Huxley et al., 1987).  
Although there has been some indication that natriuretic 
peptides are involved in inhibitory regulation of GI function (Ebert, 
1988; Olsson & Holmgren, 2001), our findings are the first to 
document a specific inhibitory role for BNP on emptying and absorptive 
functions in the GI tract.  
The average plasma BNP levels immediately after injection 
averaged 4500 pg/ml. While this level is supra-physiological, it is not 
uncommon in patients with heart failure (Fitzgerald et al., 2005). 
Furthermore, even much higher levels of BNP are consistently seen 
when recombinant BNP (Nesiritide) is administered for the treatment 
of heart failure (Colucci et al., 2000). Moreover, the BNP level in our 
experiments fell to levels routinely seen in heart failure patients at 30 
minutes post injection. Therefore, our experimental model provides 
novel insight into what would be expected in heart failure or when BNP 
is exogenously administered.  
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Natriuretic peptides bind to transmembrane receptors that have 
guanylyl cyclase (GC) activity. ANP and BNP bind to NPR-A where as 
CNP binds to NPR-B. The ensuing peptide receptor interaction 
increases intracellular cGMP with subsequent enzymatic steps that 
regulate cellular functions in various tissues where these peptides 
and/or receptors are expressed (Kuhn, 2005).  
In our study, NPR-A KO mice did not show a significant response 
with any of the peptides we used (ANP, BNP, CNP or c-ANP4-23). This 
suggests that; the gastrointestinal effects of BNP and the other 
natriuretic peptides are likely to be specifically mediated by the NPR-A 
receptor. Since c-ANP4-23 specifically binds to NPR-C (Anand-
Srivastava, 2005), the absence of a GI effect when c-ANP4-23 was 
injected into WT or NPR-A KO mice is additional evidence that NPR-A 
may be the major receptor mediating the effect of BNP on gastric 
emptying and absorption. Our finding is consistent with previous 
studies that have shown that the inhibitory effect of CNP on isolated 
gastric smooth muscle cells is mediated by a cGMP-dependent 
pathway (GuoCai et al., 2003; Scotland et al., 2005).  
The natriuretic peptides in general are among some of the most 
evolutionarily conserved peptides across many species of the 
phylogenetic tree with various functions in fluid homeostasis. Studies 
done early in the discovery of natriuretic peptides have reported that 
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ANP significantly decreased jejunal fluid absorption in dogs and rats 
(Morita et al., 1992; Scott & Maric, 1991). More recent studies have 
shown that natriuretic peptides cause upregulation of aquaporin 3 
expressions in human colonic epithelia signifying their potential role in 
fluid homeostasis (Pacha, 2000). ANP has also been shown to be 
important in promoting sea water adaptation in eels and decreases 
intestinal sodium absorption (Tsukada et al., 2005). However, the 
great majority of recent studies done on BNP have focused on its role 
in modulating blood pressure, diuresis and natriuresis. Since the 
primary stimulus for release of ANP and BNP is mechanical stretch of 
the atrial and ventricular myocardium, their expression and release is 
closely linked to body fluid volume status (Cowie & Mendez, 2002; 
James et al., 2005). Moreover, the temporal pattern of expression and 
release of BNP following a given stimulus, such as an acute myocardial 
infarction, indicates that the endocrine heart could potentially employ 
varying plasma levels of the natriuretic peptides to modulate body 
fluid volume (Silver, 2006). Since natriuretic peptide receptors are 
expressed on the gastric and intestinal smooth muscle cells, and we 
show that intravenously administered BNP decreased gastric emptying 
and absorption, it is logical to deduce that our finding may be an 
indication that the endocrine heart employs natriuretic peptides to 
delay or modulate the rate and amount of water and solute absorption 
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from the gastrointetsinal tract. From a physiological stand point the 
effect of cardiac hormones on absorption in the GI tract is a beneficial 
extension of their role in volume homeostasis. Theoretically, such a 
role could extend to pathophysiological states such as heart failure 
where plasma BNP levels and volume overload progressively rise 
(Barclay et al., 2006) and modulation of volume status becomes even 
more critical for survival.  
We have shown that high plasma levels of BNP (sustained levels 
of 500 pg/ml or greater), significantly decrease gastric motility, 
emptying and absorption in mice. This appears to be a common effect 
of the natriuretic peptides shared by ANP and CNP. The absence of this 
GI effect in receptor knockout mice and the dose-response relationship 
suggests a receptor mediated specific event.  
While our study in the mouse model can not be generalized to 
humans, our findings that BNP significantly decreased gastric emptying 
and absorption offers valuable new insights into the role of the 
gastrointestinal tract in fluid homeostasis, especially during heart 
failure. First, symptoms of perturbed gastrointestinal function such as 
nausea, dyspepsia, indigestion and malabsorption are frequently seen 
in patients with heart failure where plasma BNP levels are markedly 
elevated (Krack et al., 2005; Shamsham & Mitchell, 2000). Our study 
suggests that some of these symptoms could at least partly be 
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attributable to the elevated BNP. Secondly, such an effect by BNP 
could potentially add a new area of interest and investigation in the 
role of the heart as an endocrine organ. While there are established 
physiological and pathophysiological cardio-renal regulatory pathways; 
a possible ‘cardio-gastric and/or cardio-intestinal’ link via natriuretic 
peptides appears to be another possible pathway involving the 
endocrine heart.  
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CHAPTER FOUR 
 
 
THE ROLE OF BNP IN THE GASTRROINETESINAL  
 
MANIFESTATION OF MYOCARDIAL INJURY 
 
 
 
INTRODCUTION 
 
 Prior studies have utilized myocardial injury models to 
study pathophysiological and histological effects exerted by the 
natriuretic peptides on the cardiovascular system. Based on the results 
of our experiments reported in the earlier chapters, mainly the fact 
that the natriuretic peptides in general and BNP in particular decrease 
gastric emptying and absorption; we postulated that these peptides 
would have a similar effect in the face of acute myocardial infarction.  
The most commonly used methods of inducing experimental 
ischemia or myocardial infarction (MI) in mice are the permanent 
ligation of left anterior descending (LAD) coronary artery and the 
Cryoinfarction (freeze-thaw) method. In LAD ligation, the artery is tied 
with surgical sutures whereas in cryoinfarction a blunt frozen metallic 
probe is directly applied to a specific area of the myocardium with 
resulting thermal ischemia at the point of contact and surrounding 
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myocardium. Although the cryoinfarction method was introduced as 
early as 1948 (Hass & Taylor, 1948) it is only recently that it is shown 
to have several advantages over LAD ligation; as the LAD method is 
associated with marked variability in the size of the infarct and leads 
to apical infarct resulting in ventricular aneurysm (van den Bos et al., 
2005). In the cryoinjury model the infarct area is limited to the 
anterior wall of the myocardium more closely resembling what is 
encountered in clinical practice in humans; where reperfusion therapy 
results in limited infarct size and chances of developing apical 
aneurysm are becoming increasingly less likely (Huwer et al., 1998; 
Roell et al., 2002; van den Bos et al., 2005). Pathophysiologically, The 
cryoinfarction method causes acute cell death probably from the 
mechanical process associated with thermal injury; the infarct border 
therefore corresponds to the size of the probe hence the improved 
consistency of the resulting infarction as compared to the LAD ligation 
method (van den Bos et al., 2005). Moreover since the cryoinfarction 
method has a much lower peri and post operative mortality, fewer 
numbers of animals will be needed for a given study. 
We used a cryoinfarction model as the degree and distribution of 
the infarct (Cell death and fibrosis) is more consistent with the 
cryoinfarction as compared to the Left anterior descending artery 
(LAD) ligation method (Huwer et al., 1998; Roell et al., 2002).  
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This study was designed to test whether a cryoinfarction of the 
myocardium leads to change in gastric emptying and absorption in 
mice and whether the difference in the plasma BNP levels between the 
MI and Sham mice is responsible for this difference. The study was 
also done in NPR-A knock out mice to test whether this effect is 
mediated by NPR-A as shown by our previous experiments. 
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RESULTS 
 As shown in figure 20, our cryoinfarction model produced 
myocardial cell death and fibrosis similar to what will be seen in 
myocardial infarction. The infarction was limited to the area under the 
application of the frozen probe and immediate surrounding myocardial 
tissue without extension to the ventricular apex. AS a result no 
ventricular aneurysms were observed in our model.  
We tested and compared the degree of gastric emptying at one 
and two week after infarction to establish the differences in plasma 
BNP levels between the MI and sham mice. Subsequent experiments 
on absorption were done at two weeks after infarction. 
When gastric emptying was measured one week after infarction, 
it was significantly decreased in the cryoinfarction group as compared 
to the sham. Percent gastric emptying was 67.5% ± 5.8 for the MI 
group vs. 88.7%   ± 2.9 for the sham group (P<0.05, t-test) as shown 
in figure 21. The plasma BNP levels were elevated in both groups but 
significantly higher in the MI group as compared to the sham group.  
BNP levels were 4292.2 ± 276.5 1 week after MI vs. 105.4 ± 
11.3 in sham mice (n = 5, p<0.05, t test). BNP levels were 1964.7 ± 
755 two weeks after MI, (n=5, p<0.05, t test compared to one week 
post MI). 
  
Figure 20. Representative histological appearance of the  
                 myocardium14 days after cryoinfarction. 
                            Stain: Hematoxylin & Eosin 
                   4x (Top); 20x of the boxed part (Bottom) 
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Figure 21. Comparison of percent gastric emptying in sham vs.   
                   
      MI in Wild Type mice; one week after cryoinfarction 
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WT mice, 67.5% ± 5.8% for mice with MI vs. 88.7± 2.9 % for  
 
sham (n=7, P<0.05) 
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Figure 22. Comparison of percent gastric emptying in sham vs.  
                
          MI Wild Type mice, two weeks after cryoinfarction 
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WT mice, 82.2% ± 0.5% for mice with MI vs. 97.9 ± 0.4 % for  
 
sham (n=5, P<0.05) P= 0.017. 
 
 
 
As shown in figure 22 above, two weeks after infarction, percent 
gastric emptying values were also significantly lower in the MI group 
as compared to the sham group 82.2% ± 0.5% for MI vs. 97.9 ± 0.4 
% for sham (n=5, P<0.05).  
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Figure 23. Comparison of Percent gastric emptying in sham vs.  
                  
                MI NPR-A KO mice, two weeks after cryoinfarction 
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KO mice, 84.6% ± 0.7% for mice with MI vs. 87.6 ± 054 % for  
 
sham (n=6, P >0.05) P= 0.07 
 
In NPR-A knock out mice, percent gastric emptying was identical 
between the MI vs. the sham group 84.6% ± 0.7% for mice with MI 
vs. 87.6 ± 054 % for sham (n=6, P >0.05).  
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 There was also a statically significant difference in the degree of 
absorption measured in relative fluorescence units (RFU) in the plasma 
following a gavage meal containing 22ml/kg of 22mg/ml 4 kDa FITC 
dextran. In wild type mice, absorption was, 631.9 ± 121 (RFU)   for 
the MI group vs. 349.8 ± 78.6 (RFU) for the sham group; n=6, P< 
0.05.  
Figure 24. Comparison of absorption measured in relative  
                   
                Plasma fluorescence units. Sham vs. MI, WT mice 
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Absorption measured in Relative plasma fluorescence units  
 
WT mice, 631.9 ± 121 for mice with MI vs. 349.8 ± 78.6 for sham  
 
n=6, P< 0.05   (P=0.04) 
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In NPR-A knockout mice the difference in absorption was not 
statistically significant. Absorption measured in Relative plasma 
fluorescence units in NPR-A KO mice was, 516.2 ± 107.3 for mice with 
MI vs. 366.5 ± 39 for sham n=6, P> 0.05   (P=0.1). 
 
Figure 25. Comparison of absorption measured in relative 
                   
                  plasma fluorescence units. Sham vs. MI, NPR-A KO 
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Absorption measured in Relative plasma fluorescence units  
NPR-A KO mice, 516.2 ± 107.3 for mice with MI vs. 366.5 ± 39 for 
sham n=6, P> 0.05   (P=0.1).  
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DISCUSSION 
The presence of dyspeptic symptoms in heart failure and during 
acute myocardial ischemia has been known for a long time. Studies 
done as early as 1966 have reported what was then described as 
venostatic gastritis where venous congestion is believed to be the 
cause of gastric pathology (Fixa et al., 1966). The presence of nausea, 
vomiting and indigestion during acute myocardial infarction and in the 
course of heart failure has also been extensively reported in the 
literature (Abrahamsson & Thorén, 1973; Ahmed et al., 1978; 
Camurça et al., 2004; Pasini et al., 1989; Wei 1988). Studies that 
have looked into mechanisms of such an association have in the past 
mainly pointed to a possible chemoreceptive or neurally mediated 
reflex known as the Bezold-Jarish reflex (Chianca et al., 1997; Sleight, 
1981).  
Both ANP and BNP have previously been shown to have 
cardioprotective effect during acute myocardial infarction. For 
instance, the effect of ANP and BNP on renal salt handling was shown 
to be specifically enhanced during acute myocardial ischemia 
irrespective of the level of activation of the renin angiotensin 
aldosterone (RAS) system (Charles et al., 2003; Rademaker et al., 
2000). ANP was also shown to have important volume regulation role 
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during acute heart failure induced by ventricular pacing (Lee et al., 
1989). Both BNP and ANP are also shown to have an inhibitory effect 
on regional sympathetic activity in the kidney and the heart (Brunner-
La Rocca et al., 2001). While the pathways that lead to sympathetic 
activity are not clearly understood, the end result of decreased 
sympathetic activity is cardioprotective. Studies that looked at the 
receptors involved in such processes have consistently shown that 
these effects are mediated by cGMP coupled pathways. While some of 
this effect is indirectly mediated via the renin angiotensin aldoseterone 
(RAS) system, protective actions of guanylyl cyclase-A that are not 
mediated by the RAS have also been shown (Li et al., 2002; Nakanishi 
et al., 2005). 
In our experiments, we tested the effect of acute myocardial 
injury on gastric emptying at one and two weeks post infarction and 
compared the results along with the plasma BNP levels. There was a 
significant reduction in gastric emptying at one week in mice with 
myocardial infarction compared to sham. It is interesting to note that 
even the sham mice had a slightly lower rate of gastric emptying at 
one week compared to controls (baseline values). As the BNP levels 
were higher in sham mice than in controls, and the levels were 
markedly higher in the infarcted mice than the sham mice, this is an 
indication that BNP levels corresponded with the degree of gastric 
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emptying. At two weeks post infarction, the sham mice had gastric 
emptying statistically identical to controls where as infarcted mice 
continue to show a markedly lower rate of gastric emptying, this again 
indicates that the BNP levels significantly correspond with the degree 
of gastric emptying adding evidence that BNP may be the major (or 
one of the major) reasons for the observed differences. Since our data 
shows that infarcted receptor knock out mice had no significant 
difference in gastric emptying compared to sham, this validates our 
assertion that the BNP difference played a role in the observed effect 
and this effect is probably mediated through the NPR-A receptor.  
Our absorption data for wild type mice is consistent with our 
central hypothesis and infarcted mice did show significantly lower 
absorption rate as compared to sham. The data in the knock out mice 
in our experiment is less conclusive, since the knock out mice with MI 
did show a reduced absorption compared to the sham mice. There are 
several explanations for this finding. First of all, myocardial injury is 
known to activate a series of systems other than the natriuretic 
peptides, and secondly the process of absorption in the GI tract is also 
likely to involve several different mechanisms. For instance the renin 
angiotensin aldoseterone system is known to be activated with 
myocardial injury, inflammatory mediators such as tissue growth 
factor β and tumor necrosis factor are also a few of the cytokines that 
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are released from infarcted myocardium and circulate in the plasma 
with potential effects in the GI tract. Therefore the observed effects in 
NPR-A knock out mice may be manifestations of activation of these 
systems that would be expected to be intact in the NPR-A knock out 
mice.  
It has also been shown that intravenous volume expansion 
decreased gastric emptying and permeability of the mucosa to water 
and solutes and vagus nerve mediated neural mechanism were 
postulated as mechanisms for such an effect (Chang EB and Rao MC., 
1994). It was also reported that acute blood volume expansion with 
intravenous fluids decreased net sodium absorption in the jejunum of 
rats and dogs (Duffy et al., 1978; Richet & Hornych, 1969). Moreover 
experiments in human volunteers have shown that body position 
changes such as recumbency and simulation of hemorrhage resulted in 
significant increase in intestinal water and salt absorption (Sjövall et 
al., 1986). Despite this known relationship between gut motility, 
gastric emptying and intestinal absorption on one hand and 
intravenous venous expansion and contraction on the other, most of 
the studies that have investigated this relationship were limited to the 
vagal or sympathetic nervous system. Nevertheless, with the 
knowledge base accumulated in the field of natriuretic peptides over 
the past two decades, it is only logical to conjecture that at least some 
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of the changes observed in gastric emptying and intestinal absorption 
during acute MI or heart failure may be due to natriuretic peptides.  
The data supporting the relationship between volume expansion 
and gastric emptying and intestinal water and salt absorption is fairly 
strong. What was missing was an experiment to directly and 
specifically test whether the elevated natriuretic peptide levels (caused 
by volume expansion or myocardial injury) corresponded with gastric 
contractility, gastric emptying and absorption. Together with our 
earlier findings that all the natriuretic peptides significantly decrease 
gastric contractility, our data on BNP showing significant reduction of 
gastric emptying and absorption; the confirmation of these findings in 
an acute myocardial infarction model is a strong indication that plasma 
BNP (and natriuretic peptide) elevation during acute MI and / or heart 
failure is at least partly responsible for these observed effects. More 
importantly, the previously confirmed effect of increased plasma 
volume on gastric emptying and absorption is validated by our data to 
be mediated by natriuretic peptides in general and by BNP in 
particular. This finding strengthens the case for a humoral link 
between the heart and the GI tract and opens up new avenues for 
heart failure research. We believe further research in this area could 
identify potential new targets for the treatment of heart failure.   
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CHAPTER FIVE 
 
 
BNP AND NON MUSCLE MYOSINS IN THE  
 
GASTROINTETSINAL TRACT 
 
 
INTRODUCTION 
 
Myosins are proteins that are involved in mechanical force 
generation and transduction. The characteristic myosin molecule is 
composed of two heavy chain subunits measuring approximately 200 
kDa each, which form a globular amino-terminal head region, and a 
coiled carboxyl-terminal tail. The globular head region is non-
covalently associated with two pairs of light chains of 20 and 17 kDa 
(Kelley & Adelstein, 1990). Typically, myosins interact with another 
protein; actin, in a process that involves the hydrolysis of ATP. 
Classically such actomyosin interaction is discussed in the context of 
muscle contraction and relaxation. However myosins are also 
expressed in non muscle tissue (Sellers, 2000).  
 
 
 
 Figure 26.  Schematic diagram of non muscle myosin-II 
 
 
 
Adapted from Bresnick (1999) 
 
In non muscle cells, the prototype non muscle myosin 
type-II regulates actin organization into filaments and its 
functions include maintaining the cell shape, cell division and cell 
movement (Bresnick, 1999). Non muscle myosin-II is also 
involved in epithelial cell attachment at the tight junction 
regulating paracellular permeability (Hecht et al., 1996). Tight 
junctions are integral part of the intestinal villi absorptive 
structures. 
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Intestinal Villi 
 
Figure 27. Schematic depiction and electron micrograph of  
 
the structures of intestinal villi  
 
 
 79
                                                   
 
  
Adapted from Keith R. Porter and S Clark 
 
The electron micrograph (above) shows the microvilli of a mouse 
intestinal cell.  Incorporated in the plasma membrane of the microvilli 
are a number of enzymes, mucous producing goblet cells and 
endocrine / paracrine cells that produce a number of hormones, 
among which are the natriuretic peptides and guanylins.  
Figure 28. Cytoskeletal structures of the intestinal microvillus.                 
 
 
 
 
 
 
Adapted from Ross, Histology:  A Text and Atlas, 4th ed.  
 
 
 
 
 
 
 80
Figure 29. Ultra structures of the microvilli cytoskeleton  
            
 
 A 
 
 
 B 
 
Adapted from (Hirokawa & Heuser, 1981) 
 
Actin cytoskeleton is shown by the arrow(s) in panel A, and in panel B 
the quick freeze, deep etch, rotary replication images show the core of 
the microvilli and its attachment at the cytoskeleton base in the 
cytoplasm  
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Figure 30. Transmission Electron micrograph of intestinal villi   
  
                    in various state of contraction 
 
 
 
       
Chicken intestinal epithelia showing increasing state of 
contraction (top to bottom). Note ‘fanning’ of the microvilli as 
the degree of contraction increase. Transmission electron 
micrograph. Top; 6100x, middle; 5600 x and bottom 8900x. 
 
Adapted from (Burgess, 1982) 
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Tight Junctions 
Tight junctions seal adjacent epithelial cells in a narrow band 
just beneath their apical surface. They perform vital functions including 
regulation of the passage of molecules and ions through the space 
between cells and blocking of movement of the integral membrane 
proteins between the apical and basolateral surfaces. 
 
 
Figure 31. Schematic depiction of tight junctions 
 
 
 
 
 
              
Studies done in kidney, bladder and intestinal epithelia 
have confirmed changes in permeability regulated by 
Phosphorylation related contractile changes at the tight junction. 
These changes primarily increase paracellular movement of 
water and small molecular weight solutes (Broschat et al., 1983; 
Hecht et al., 1996; Keller & Mooseker, 1982; Swanljung-Collins 
& Collins, 1992). Non muscle myosin type IIB is phosphorylated 
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by casein kinase-II and dephosphorylated by a phosphatase that 
is regulated through the action of Rho–associated kinase (Li & 
Gorodeski, 2006).  
Since the physiological effects of the natriuretic peptides 
are mediated via cGMP dependant protein kinases, we found it 
intriguing to examine whether treatment with BNP would reveal 
changes in the distribution of non muscle myosins and 
contractility pattern of the intestinal villi and thus shed some 
light on the mechanism for the observed effect of BNP on 
absorption.   
We treated wild type mice with a 10 ng/g iv bolus of BNP 
followed by a 1ng/minute infusion for 30 minutes. After the 30 
minute infusion the mice were sacrificed and intestinal tissue 
removed and sectioned into, jejunum, ileum and colon and 
immunostained for non muscle myosin as described in the 
methods section. We used the vehicle as an experimental 
control. We also used a tissue section not treated with first 
antibody as a methodological control to evaluate the potential 
confounding by non specific binding. 
 
 
 
 
 
RESULTS 
 
Figure 32. Toluidine blue stained 3µm sections of a mouse  
 
         intestinal tissues 
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Cross sections of intestinal tissue from our experiments are shown. 
Top panel, Jejunum; middle panel, ileum; and bottom panel, colon.  
 
Figure 33. Higher magnification view of intestinal villi 
 
 
 
 
 
 
Images shown are 3 µm section of Jejunal villi (top) and Ileum  
 
(bottom), stained with toluidine blue.  Magnification is 40x top, and  
 
20x bottom. 
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Figure 34. Electron micrograph of the intestinal microvilli 
           
           Control vs. BNP treated 
 
 
      
 
        Control, 20 000x  BNP treated, 20 000x 
 
 
 
 
Microvilli in BNP treated mice show loss of the distinctive 
‘fanning’ of the microvilli that is typical of markedly contracted 
state.  
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Figure 35. Jejunal villi immunostained for non muscle  
 
        myosin type IIB - Control 
 
 
 
 
 
Longitudinal section at 20x (Top) and cross section 40x bottom 
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Figure 36. Comparative images of control vs. BNP treated  
 
           jejunal villi 
 
 
 
 
 
 
Images show jejunal villi, immunostained for non muscle myosin 
type IIB. Control (TOP) and BNP treated (bottom). Note the 
marked increase in fluorescence in BNP treated as compared to 
control. Immunofluorescence, 20 x magnification.  
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 Figure 37. Jejunal villi and smooth muscle bundles  
 
              immunostained for non muscle myosin  
 
 
 
 
 
Cross section view of the mouse ileum is shown. Note the 
circular and longitudinal smooth muscle bundles with distinct 
stain (fluorescence) for non muscle myosin type IIB.  The core of 
the villi also shows the distinct staining pattern.  
Magnification, 10 x 
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Figure 38. A 3 µm sections of a mouse jejunum immunostained  
 
                for non muscle myosin type IIB. Control vs. BNP 
 
 
                      
 
 
Control top and BNP treated bottom. Note the markedly increased  
 
staining of the villus core and the crypt in BNP treated mouse. 20x 
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DISCUSSION 
 
 
   Structures necessary for force generation and 
mechanotransduction such as actin and myosin and their 
associated proteins are integral components of the cytoskeleton 
of the intestinal villi (Mooseker, 1976; Mooseker et al., 1983; 
Rodewald et al., 1976; Rostgaard & Thuneberg, 1972). Although 
the mechanism of contraction of intestinal villi still remains 
unsettled, different studies have reported mechanisms of 
contraction that are both ATP and calcium dependent and others 
reporting calcium independent mechanisms of contraction 
(Burgess, 1982; Mooseker, 1976; Swanljung-Collins & Collins, 
1991). Still other studies have reported contraction at the tight 
junctions but not of the microvilli themselves (Keller & Mooseker, 
1982).     
      Our electron micrographic observations indicate that 
elevation of BNP in the plasma appears to cause the microvilli to 
loose the typical ‘fanning’ or separated appearance that is 
characteristic of contraction at the crypt region of the intestinal 
microvilli. Such appearance was previously shown to be due to 
contraction at the tight junction regions involving a 
circumferential contractile ring (Burgess, 1982).  Tight junction 
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contraction in turn results in increased paracellular permeability 
(Hecht et al., 1996; Turner et al., 1997). Therefore our electron 
micrographic observation (decreased contraction of the tight 
junction contractile ring) supports the hypothesis that elevated 
BNP in the plasma makes the tight junctions of intestinal villi less 
permeable to water and small molecular weight solutes. Our 
fluorescence immunostaining images also support this 
hypothesis as we show enhanced distribution of non muscle 
myosins along the crypts of the villi; which may be an indication 
that the enhanced distribution corresponds to a change in  
tautness of the tight junctions thereby decreasing paracellular 
movement while allowing apical transport of nutrients. Apical 
transport of electrolytes and nutrients (sodium and glucose for 
example) is mediated by the sodium glucose cotransporter 
(SGLT1) and is accompanied by increased tight junction 
permeability to small solutes (Turner et al., 1997). 
Physiologically such coordination between the apical and 
basolateral surfaces of the villus would be advantageous; as it 
allows regulated (transporter mediated) absorption across the 
apical membrane while directing water and small solutes to the 
tight junction. However whenever there is a need to decreases 
volume, as in the case of heart failure; decreasing free 
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paracellular movement of water while still permitting apical 
transport of nutrients would allow for a more homeostatic 
absorptive function; especially when modulating volume 
becomes essential as in the case of heart failure. Utilizing BNP 
and possibly the other natriuretic peptides for this process would 
have physiological benefit for the heart; after all the heart will be 
‘interested’ in getting all the nutrients it can get during heart 
failure while delaying or decreasing absorption of water and salt 
that could add to its stress.  
  Although the effect of BNP and natriuretic peptides in 
general on permeability of intestinal epithelia has not been 
extensively studied in the past, it is known that natriuretic 
peptides in general have an effect on permeability of the 
vascular epithelium (He et al., 1998; Huxley et al., 1987; Kubes, 
1993; Lofton et al., 1990). Studies that have looked into this 
effect of ANP and BNP on permeability of  pulmonary vascular 
epithelium have shown that these effects were at least partially 
reproduced by cGMP or cGMP analogs (Draijer et al., 1995; 
Hölschermann et al., 1997; Klinger et al., 2006; Westendorp et 
al., 1994). A more direct effect that is independent of cGMP was 
also shown for ANP (Kubes, 1993). Similarly, other studies that 
have investigated the effect of ANP on counteracting the 
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endothelial permeability and inflammatory effect of  tumor 
necrosis factor (TNF) have shown that this effect is mediated by 
NPR-A and cGMP and it is targeted at cytoskeletal actin 
organization (Kiemer et al., 2002).  An other support for this 
finding comes from the observation that vascular endothelial 
growth factor (VEGF) is inhibited by ANP (Pedram et al., 2002). 
VEGF is also known as vascular permeability factor and is 
involved in stabilization of  actin association with tight junctions; 
and this function was reversed by guanylyl cyclase receptor 
antagonists (Pedram et al., 2002). The precise mechanism of 
this process is still unclear, some studies indicated it involves 
heat shock protein 27 (HSP27); a protein with known functions 
in  actin organization and whose actions are mediated by cGMP 
dependent protein kinase (Butt et al., 2001). Other studies 
suggest mechanisms that involve Phosphorylation of structural 
and contractile proteins; including actin and  myosin (Hecht et 
al., 1996; Ma et al., 2000; Turner et al., 1997), Specifically at 
the prejunctional ring of actin and myosin; sites that are 
characteristic of contractile function at the tight junction (Madara 
et al., 1987).  
Our immunofluorescene images revealed an enhanced 
distribution of non muscle myosins in the intestinal villi core and 
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along the crypts (tight junctions). While we haven’t done 
biochemical analysis to correspond with these findings, previous 
studies have shown that Phosphorylation related proteins such 
as mitogen-activated protein (MAP) kinase and Rho of the ras 
family of proteins are associated with tight junctions and this in 
turn controls tight junction contractility (Murakami et al., 1994; 
Zahraoui et al., 1994). Interestingly, both ANP and BNP are 
known to exert anti inflammatory (thus decreased vascular 
endothelium permeability) effects in vascular endothelium 
through mechanisms that involve MAP-kinase and MAP kinase 
phosphatase-1 (MKP-1) (Fürst et al., 2005; Weber et al., 2003).  
Although more research needs to be done in this direction, 
our electron micrographic imaging and immunostaining data 
coupled with what is previously known about epithelial tight 
junction function lends enough support to our hypothesis and 
helps formulate a basis for future direction. The finding that 
immunostaining of non muscle myosin in BNP treated mouse 
tissue shows enhanced distribution of non muscle myosins along 
the crypts and core of the intestinal microvillus appears to be a 
recurring theme. Tight junctions appear to contract less and 
microvilli assume the typical non-contracting appearance when 
BNP plasma level was raised. These findings are associated with 
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decreased paracellular permeability at least in the case of the 
vascular endothelium. Whether the biochemical signaling 
mechanisms known for vascular endothelium will be the same in 
the intestinal villi and whether it will have similar physiological 
consequences remains to be investigated.  
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CHAPTER SIX 
 
SUMMARY AND CONCLUSIONS 
 
 
The main objective of my study was to show that there indeed is 
a humoral link between the heart and the gastrointestinal system. This 
humoral link appears to utilize natriuretic peptides although it is 
possible that there probably are several other as yet undiscovered 
peptides or even other molecules that serve this same purpose.   
To this aim, we demonstrated that ANP, BNP and CNP decreased 
contractility of gastric smooth muscle in the whole intact animal. 
Confirming the previously done in vitro experiments that showed 
natriuretic peptides decreased contractility of isolated gastric and 
intestinal smooth muscle cells. This effect was shown to have a 
functional significance in that; these experiments showed that gastric 
emptying and absorption from the gut were decreased in the whole 
animal when BNP was intravenously administered. We also presented 
data showing myocardial injury and the associated elevation in plasma 
BNP levels decreased gastric emptying and absorption from the GI 
tract. Although the obvious reason for this result may be the effect of 
BNP on smooth muscle relaxation, we also show data supporting the 
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hypothesis that BNP and natriuretic peptides have a more direct effect 
on absorptive structures of the intestinal villi possibly affecting 
paracellular transport of water and electrolytes.  
In summary one can garner the following observations from 
these experiments 
a) Natriuretic peptides decrease gastric contractility and gastric 
emptying in intact whole animals 
b) BNP decreased gastric empting in a dose dependant manner 
c) BNP decreased absorption from the GI tract when administered 
at dose designed to raise the plasma level to the levels seen in 
heart failure 
d) Myocardial injury and elevation of BNP in the plasma was 
associated with decreased gastric emptying and absorption 
e) Elevated plasma BNP has en effect on contractile structures of 
the intestinal villi and this effect appears to be directed at 
decreasing paracellular movement of water and solutes 
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PERSPECTIVES 
 
The next line of research should follow the intriguing questions 
raised by our immunofluorescnece data. How and why does the 
distribution of myosin in the microvilli appear to be increased by BNP? 
What are the molecular mechanisms that are involved here? Is the 
electron micrograph appearance of microvilli indication of contraction 
at the tight junction? Is paracellular movement of water and solutes 
decreased by BNP as suggested by our imaging data? Are there other 
transporters that direct water and sodium absorption to the basal and 
apical membranes; if so can they be therapeutically targeted to 
regulate sodium absorption from the gut? Would that be beneficial in 
heart failure treatment?  
Heart failure remains to be a major public health problem. Its 
annual cost to the health care field is growing every year and currently 
stands at over 30 Billon US dollars. Despite remarkable advances in 
the treatment of coronary disease and the risk factors associated with 
it, the incidence and prevalence of heart failure has only increased. In 
spite of all this, there hasn’t been a major breakthrough in heart 
failure treatment for many decades. Of course targeting the gut to 
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treat the heart seems a bit far fetched at this point in time. However, 
the GI tract is a complex organ, perhaps even tantamount to having 
many organs in one. The experimental results presented here 
strengthen the case for a direct humoral link and interplay between 
the heart and the GI tract. Further understanding of this link and 
characterization of the signaling process involved is likely to be a 
major advance in heart failure treatment. 
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APPENDIX A 
 
 Abbreviations Used 
 
 
ACE – Angiotensin converting enzyme 
 
ANF - Atrial natriuretic factor 
 
ANOVA - Analysis of variance 
 
ANP – Atrial natriuretic peptide 
 
AT1 – Angiotensin II receptor type 1A 
 
BNP – B-type natriuretic peptide 
 
cANF – c-Atrial natriuretic factor (peptide) 
 
cGMP – Cyclic guanylyl mono phosphate 
 
CNP – C-type natriuretic peptide 
 
DMSO – Dimethyl sulfoxide 
 
DNP – Deandropsis natriuretic peptide 
 
FITC – Fluorescein-isothiocyanate   
 
GC – guanylyl cyclase 
 
GI – Gastrointestinal 
 
GTP – Guanylyl tri phosphate 
 
i.d. – Internal diameter 
 
i.v. – Intravenous 
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i.P. – Intraperiotneal 
 
KDa – Kilo Dalton 
 
KHD – Kinase homology domain 
 
KO – Knockout 
 
LAD – Left anterior descending artery 
 
LSD – Least square difference 
 
LV – Left ventricle 
 
MAP – Mitogen activated pathway 
 
MI – Myocardial infarction 
 
MKP – Mitogen activated kinase phosphatase 
 
NPR-A – Natriuretic peptide receptor type –A 
 
NPR-B - Natriuretic peptide receptor type –B 
 
NPR-C - Natriuretic peptide receptor type –C 
 
o.d. – Outside diameter 
 
PBS – Phosphate buffered saline 
 
PDE – Phosphodiesterase 
 
PIC- Probe induction catheter 
 
PKG – Protein kinase G 
 
RFU – Relative fluorescence units 
 
RIA – Radioimmunoassay 
 
RV – Right ventricle 
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TNF – Tumor necrosis factor 
 
VEGF – Vascular endothelium derived growth factor 
 
WT – Wild type 
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